Bita Fakhri
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
Oncogenic mutations of SF3B1 are common in myeloid cancers, chronic lymphocytic leukemia (CLL) and select solid tumors. Their mechanistic basis for promoting oncogenesis has been investigated in detail, with the stereotyped missplicing of mRNA protein coding sequences most intensively studied. These changes, in genes such as MAP3K7, BRD9, and ABCB7, typically lead to loss-of-function, thus contributing to cancer pathogenesis.Here we systematically analyzed the impact of mutant SF3B1 on non-coding regions of mRNA transcripts across disease types, in both cell lines and primary patient specimens. This identified numerous novel and highly reproducible splicing alterations in such regions. Studies of one target gene, DCAF16, revealed multiple complex mutation-induced alterations in its 5' and 3' untranslated regions (5', 3' UTRs). Remarkably, these were mechanistically associated with increased DCAF16 protein levels in SF3B1 mutant cells, representing the first time that oncogenic SF3B1 has been shown to increase levels of a target protein in a gain-of-function manner. DCAF16 is a substrate recognition adapter for the DDB1/CUL4 E3 ubiquitin ligase complex. Novel protein degrader small molecules which co-opt DCAF16 to degrade BRD4 as a neosubstrate demonstrated preferential selectivity for SF3B1 mutant cancers and CLL primary patient specimens due to increased DCAF16 protein levels. In turn, this reveals the therapeutic relevance of mutant SF3B1 dysregulation of transcript untranslated regions and uncovers a novel strategy for the treatment of these important neoplasms.
Year:
2026
Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies that have a natural history that follows a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy with or in combination with chemotherapy (chemoimmunotherapy), with second-line options such as covalent (c) Bruton tyrosine kinase inhibitors (BTKi). However, management of relapsed and refractory (R/R) MZL remains a challenge. Pirtobrutinib, a highly selective, non-covalent BTKi has shown promising efficacy and tolerability in patients with poor-prognosis B-cell malignancies following prior therapy, including cBTKi. Here we report the safety and efficacy of pirtobrutinib in patients with MZL from the phase 1/2 BRUIN study. Endpoints included investigator assessed ORR by Lugano 2014 criteria, DOR, PFS, OS, and safety. Among 36 R/R MZL patients (EMZL: n=6; NMZL: n=17; SMZL: n=13), median age was 68 years (range, 22-83) and median prior lines of therapy were 3 (range, 2-10) including anti-CD-20 antibody (100%), chemotherapy (86%) and cBTKi therapy (72%). The ORR was 55.6% (95% confidence interval [CI], 38.1- 72.1) including 3 (8.3%) complete responses and 17 (47.2%) partial responses. Median DOR was 17.8 months (95%CI, 7.4-non-estimable [NE]), and median PFS was 16.6 months (95%CI, 9.0-22.1). With median follow-up of 32.4 months (IQR, 28.0, 41.3), median OS was NE (95%CI, 29.5-NE). The ORR for patients with prior cBTKi therapy was 53.8% (95%CI, 33.4-73.4). Pirtobrutinib was well-tolerated with dose reductions in 4 patients (11.1%) and permanent discontinuation due to TEAEs in 4 (11.1%). Pirtobrutinib showed promising efficacy and safety in patients with heavily pre-treated R/R MZL, including prior cBTKi. NCT03740529
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Relapsed/refractory (R/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariably experience relapse. While newer therapies such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T cell) therapy are available, patient access and eligibility remain challenging. Here, we report the safety and efficacy of pirtobrutinib, a noncovalent (reversible) BTKi monotherapy in a R/R FL cohort from the multicenter phase 1/2 BRUIN study. Key end points included investigator-assessed overall response rate (ORR) per Lugano 2014 criteria, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Among 48 patients with FL, the median age was 64.5 years (range, 37.0-85.0). Patients had received a median of 3 (range, 1-12) prior lines of therapy. The ORR with pirtobrutinib was 52.1% (95% confidence interval [CI], 37.2-66.7), and median DoR was 10.2 months (95% CI, 3.7-25.7). Median PFS was 5.8 months (95% CI, 3.8-8.1), and median OS was not estimable, with a median follow-up of 35.2 months (interquartile range, 31.1-41.8). The estimated DoR, PFS, and OS rates at 24 months were 33.3% (95% CI, 15.9-51.9), 25.6% (95% CI, 13.9-39.1), and 75.1% (95% CI, 59.5-85.4), respectively. Pirtobrutinib was well tolerated, with 2 patients (4.2%) discontinuing treatment due to adverse events (AEs; 1 treatment-related) and 4 patients (8.3%) having dose reductions due to AEs (all treatment related). Pirtobrutinib showed promising efficacy and was well tolerated in this cohort of patients with heavily pretreated R/R FL, warranting further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03740529.
Year:
2025
Year:
2025
Oncogenic mutations of the core RNA splicing factor SF3B1 are common in myeloid cancers, chronic lymphocytic leukemia (CLL) and select solid tumors, and act as clear disease drivers. Despite multiple efforts, therapeutic modulation of RNA splicing has not yet demonstrated benefit for SF3B1 mutant cancers in the clinic, and there are no FDA approved disease-modifying therapies for cancers with this mutation. This highlights an urgent unmet medical need for targeted therapies. Here we identified the first known gain-of-function target of oncogenic SF3B1, i.e. DCAF16, and exploit it to selectively target SF3B1 mutant cancers – thus demonstrating a novel therapeutic approach to this oncogene. Mutant SF3B1 drives oncogenesis through a variety of complex mechanisms. Among the best-studied are its impact on the stereotyped missplicing of mRNA coding regions (CDS) in target genes like MAP3K7 and BRD9. Ordinarily, these misspliced gene targets yield loss-of-function, contributing to disease pathogenesis. Here we systematically analyzed the impact of mutant SF3B1 on mRNA untranslated regions (UTRs) o in wildtype (WT) vs. SF3B1 mutant cancers across primary myeloid, lymphoid and solid tumors, as well as isogenic cell lines. This identified numerous novel and highly reproducible missplicing events. Among the most prominent targets with UTR missplicing is DCAF16, a substrate recognition adapter for the DDB1/CUL4 E3 ubiquitin ligase complex and emerging pharmacologic target. RNA sequencing (RNA-seq), 3' end sequencing (3'-seq), and Nanopore long read sequencing (LRS) experiments revealed complex mutation-induced alterations in DCAF16 5' and 3' UTRs. Specifically, mutant SF3B1 mediates exclusion of exons 2 and 3 in the DCAF16 5' UTR to generate CDS isoforms with an alternative 5' UTR. Further, in other isoforms mutant SF3B1 promotes use of an alternative 5' splice site in exon 4, which ordinarily contains the CDS and 3' UTR. As a result, one novel DCAF16 transcript skips the CDS to encode a long noncoding RNA (lncRNA) by inclusion of exon 5 to generate an alternative mRNA 3' end. Remarkably, mutant SF3B1 is reproducibly associated with elevated DCAF16 protein levels in multiple isogenic hematologic and solid tumor SF3B1 mutant cell lines over WT, as well as primary myeloid cancers and CLL specimens vs. WT controls. Further, DCAF16 isoforms skipping exon 3 in the 5‘ UTR, or the DCAF16 associated lncRNA, both of which are promoted by mutant SF3B1, directly cause increased DCAF16 protein levels. These transcript species and the presence of mutant SF3B1 are not associated with changes in DCAF16 mRNA half-life, subcellular localization, expression levels of its CDS, or DCAF16 protein half-life. Conversely, the presence or absence of exon 3 in dual luciferase reporter systems, as well as polysome profiling of WT vs. SF3B1 mutant cells indicate that elements within exon 3 of the DCAF16 5‘ UTR, which are misspliced by mutant SF3B1, may regulate DCAF16 translation efficiency. Together, these studies represent the first time that oncogenic SF3B1 has been shown to increase levels of a target protein in a gain-of-function manner, by altering the composition of a target gene's untranslated regions. Finally, DCAF16 is a novel target for protein degrader therapeutics such as proteolysis targeting chimeras (PROTACs) and molecular glues which co-opt it to mediate the proteosomal degradation of neosubstrates of therapeutic importance. Small molecules that utilize DCAF16 to degrade key cancer protein targets including BRD4, DYRK1A and RPS6KA4 among others demonstrated preferential selectivity for SF3B1 mutant cancer cell lines and primary CLL patient specimens due to increased DCAF16 protein. The preferential sensitivity of SF3B1 mutant cells to DCAF16-based degraders was associated with accentuated loss of protein degradation targets such as BRD4, as well as consistent alterations in downstream targets such as MYC and anti-apoptotic BH3 family members in the
Year:
2025
Introduction: Lisocabtagene maraleucel (liso-cel) was approved in the United States for the treatment of CLL in 3/2024 for patients who have received two prior lines of therapy including a covalent BTK inhibitor and a BCL-2 inhibitor. Data regarding outcomes of liso-cel is limited to reports from the registrational TRANSCEND-CLL 004 clinical trial which had strict inclusion and exclusion criteria. This work investigates the real-world efficacy and safety of liso-cel for patients with CLL and its efficacy in specific sub-populations. Methods: This is a multi-institutional retrospective study (Collaborative Assessment of Real-World Evidence of Lisocabtagene Maraleucel in Patients with Relapsed/Refractory CLL/SLL [CARE CAR-T CLL]) of patients with CLL who received commercial liso-cel in the United States. Patients with Richter transformation were excluded. Response was defined by iwCLL criteria. Patients who did not undergo a marrow biopsy but met other criteria for a complete response (CR) were categorized as unconfirmed CR (CRu). CRS and ICANS were graded per ASTCT criteria. Results: A total of 30 patients were identified with a median age of 67 years (range 44 – 80). Twenty of thirty patients (67%) had either del17p and/or mutated TP53, and 8/30 (27%) had complex karyotype (≥ 3 abnormalities) at time of liso-cel infusion. Patients received a median of 6 prior lines of therapy (range 1 - 12), and 24 (80%) were previously treated with chemotherapy. All patients had previous exposure to a covalent BTK inhibitor and a BCL-2 inhibitor. Twenty-seven (90%) of patients had prior exposure to pirtobrutinib. Twenty-nine patients (96.7%) received bridging treatment that was stopped after leukapheresis with 1 patient in CR and 25 patients in PR at time of liso-cel. Eighteen patients (60%) were treated with pirtobrutinib as the last line of treatment prior to liso-cel. Median length of time on pirtobrutinib prior to liso-cel infusion was 4 months (interquartile range [IQR], 2 – 8 months). Twelve (66.7%) patients stopped pirtobrutinib between leukapheresis and lymphodepletion, and 6 continued after liso-cel. Best CR/CRu rate was 60.0% (CR, n = 17/30; CRu, n = 1/30), and best overall response rate (ORR) was 83.3% (25/30) with median time to best response of 30 days (IQR, 28 – 30 days). Of the 18 patients who received pirtobrutinib as their last line of therapy, 13 (72%) achieved a CR/CRu. Meanwhile, of the 12 patients who did not receive pirtobrutinib as their last line of therapy, only 5 (28%) achieved a CR. Measurable residual disease testing (MRD) by flow cytometry was done in 14/30 patients, and 9 patients (64%) had achieved undetectable MRD (uMRD). MRD by next generation sequencing (NGS) was done in 17 patients, and 7 (41%) patients had uMRD. Twenty-seven of 30 patients (90%) were alive at time of data collection. Median follow-up was 3.3 months (IQR, 1.2 – 8.9 months). Twenty-six patients (87%) experienced any grade cytokine release syndrome (CRS), and 3 patients experienced grade 3 CRS (10%). Twelve patients (40%) experienced any grade immune effector cell-associated neurotoxicity syndrome (ICANS), and 4 patients (13%) experienced grade 3 ICANS. There were no grade 4 or 5 CRS or ICANS. One patient experienced grade 3 immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). At day 30, patients had a median absolute neutrophil count of 1.7K/μL (IQR, 0.8 – 3.6K/μL), hemoglobin of 11.7 g/dL (IQR, 8.6 – 13.1 g/dL), and platelet count of 72K/μL (IQR, 29 – 119K/μL). Conclusion: Real-world analysis of liso-cel for patients with relapsed/refractory CLL showed CR and ORR of 60.0% and 83.3%, respectively. Despite having a heavily pre-treated and chemotherapy-exposed population and with over half the patients having high-risk features, these response rates are higher than what was described in the TRANSCEND-CLL 004 clinical trial. These results are limited by the short follow-up period and the variability in respo
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Collaborators (11)
ANASTASIOS STATHIS
Head of Research Service and Scientific Head Clinical Trial Unit
Istituto Cantonale di Patologia
Chan Yoon Cheah
University of Western Australia
Mazyar Shadman
Fred Hutchinson Cancer Research Center
Xiaoyu Zhang
Assistant Professor
Northwestern University
Edna Cheung
Assistant Clinical Professor
University of California, San Francisco
PIER LUIGI ZINZANI
University of Bologna
Ewa Lech-Maranda
Institute of Hematology and Transfusion Medicine
Shuo Ma
Professor of Medicine
Northwestern University
Capucine Van Rechem
Associate Professor
University of Colorado Anschutz Medical Campus
Nathanael S. Gray
Stanford University
Benoit Tessoulin
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.